Physician profile
Alex G Yip
NPI 1316937477
$11,194.91
in general payments reported to CMS, 2019-2025
34 companies · $1,598 in 2025
The $1,598 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,713 · 2020: $1,189 · 2021: $2,124 · 2022: $1,570 · 2023: $1,591 · 2024: $1,409 · 2025: $1,598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,587 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,587.04 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,482.03 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Csl Behring | $1,473.85 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $1,256.89 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $890.46 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $661.56 | 2019-2025 | Nucala |
| Teva Pharmaceuticals USA, INC. | $548.06 | 2020-2023 | Airduo Digihaler |
| Takeda Pharmaceuticals U.S.A., INC. | $523.99 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Biocryst US Sales Co., LLC | $501.18 | 2021-2025 | Orladeyo |
| Grifols USA, LLC | $478.02 | 2020-2024 | Xembify, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $434.74 | 2019-2025 | |
| Genentech USA, INC. | $357.45 | 2019-2025 | Xolair |
| Optinose US, INC. | $329.80 | 2019-2025 | |
| Kaleo, INC. | $299.50 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $241.59 | 2019-2025 | |
| Amgen INC. | $232.37 | 2021-2025 | Tezspire |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $227.14 | 2019-2025 | Ruconest |
| Aimmune Therapeutics, INC. | $175.74 | 2021-2022 | |
| Leo Pharma INC. | $168.89 | 2022-2025 | Adbry, Anzupgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.19 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $145.58 | 2025 | Neffy |
| Shire North American Group INC | $141.42 | 2019 | |
| Aytu Biopharma, INC. | $112.49 | 2019-2023 | Karbinal |
| Abbvie INC. | $56.00 | 2023 | Rinvoq |
| Covis Pharma Gmbh | $48.48 | 2021 | |
| Cycle Pharmaceuticals INC | $39.31 | 2025 | Sajazir |
| Biocryst Pharmaceuticals, INC. | $31.53 | 2020 | |
| Galderma Laboratories, L.P. | $29.81 | 2025 | Nemluvio |
| Organon LLC | $27.97 | 2025 | Vtama |
| Ionis Pharmaceuticals, INC. | $26.72 | 2025 | Dawnzera |
| Paratek Pharmaceuticals, INC. | $21.47 | 2025 | Xhance |
| Horizon Therapeutics Plc | $20.68 | 2019 | |
| Azurity Pharmaceuticals, INC. | $19.53 | 2025 | Alvesco |
| Uswm, LLC | $17.00 | 2021 | |
| Lilly USA, LLC | $16.47 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Yip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.